{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:06:10Z","timestamp":1784552770252,"version":"3.55.0"},"reference-count":85,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/501100014786","name":"Northern Border University","doi-asserted-by":"publisher","award":["NBU-CRP-2026-3770"],"award-info":[{"award-number":["NBU-CRP-2026-3770"]}],"id":[{"id":"10.13039\/501100014786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14756366.2026.2660982","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:47:47Z","timestamp":1784551667000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological advances in\n                    <i>Candida auris<\/i>\n                    : emerging antifungal mechanisms and next-generation therapeutic strategies"],"prefix":"10.1080","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5765-4580","authenticated-orcid":false,"given":"Shuaibu Abdullahi","family":"Hudu","sequence":"first","affiliation":[{"name":"Center for Health Research, Northern Border University","place":["Arar, Saudi Arabia"]},{"name":"Department of Microbiology, Faculty of Medicine, Northern Border University","place":["Arar, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-6686","authenticated-orcid":false,"given":"Najlaa","family":"Saadi","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Medical Sciences, Faculty of Dentistry, Zarqa University","place":["Zarqa, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0110-2343","authenticated-orcid":false,"given":"Emad A.","family":"Morad","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Zagazig University","place":["Zagazig, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9272-5540","authenticated-orcid":false,"given":"Albashir","family":"Tahir","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Basic Medical Sciences, Sa\u2019adu Zungur University","place":["Bauchi State, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-9100","authenticated-orcid":false,"given":"Abdulgafar Olayiwola","family":"Jimoh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University","place":["Sokoto, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12539","article-title":"Global trends in the distribution of Candida species causing candidemia","volume":"20","author":"Guinea J.","year":"2014","unstructured":"Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20 Suppl 6:5\u201310.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"e_1_3_5_3_1","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00203-022-03159-3","article-title":"The use of readily available laboratory tests for the identification of the emerging yeast Candida auris in Mexico","volume":"204","author":"Gonz\u00e1lez-Dur\u00e1n E","year":"2022","unstructured":"Gonz\u00e1lez-Dur\u00e1n E, Contreras-P\u00e9rez CU, Caceres DH, R\u00edos-Rosas C, Pi\u00f1\u00f3n-Ortega JdJ, T\u00e9llez-Saucedo MD, Mar\u00edn-Suro ES, Wong-Ar\u00e1mbula CE, Moreno-Escobar EA, Ram\u00edrez-Gonz\u00e1lez JE, et al. The use of readily available laboratory tests for the identification of the emerging yeast Candida auris in Mexico. Arch Microbiol. 2022;204(9):592\u2013592.","journal-title":"Arch Microbiol"},{"issue":"2","key":"e_1_3_5_4_1","doi-asserted-by":"crossref","first-page":"01588","DOI":"10.1128\/JCM.01588-17","article-title":"Candida auris: an emerging fungal pathogen","volume":"56","author":"Spivak ES","year":"2018","unstructured":"Spivak ES, Hanson KE. Candida auris: an emerging fungal pathogen. J Clin Microbiol. 2018;56(2):01588\u201301517.","journal-title":"J Clin Microbiol"},{"key":"e_1_3_5_5_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/IDR.S116229","article-title":"Current perspective on emergence, diagnosis and drug resistance in Candida auris","volume":"10","author":"Sarma S","year":"2017","unstructured":"Sarma S, Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155\u2013165.","journal-title":"Infect Drug Resist"},{"issue":"46","key":"e_1_3_5_6_1","doi-asserted-by":"crossref","first-page":"2200846","DOI":"10.2807\/1560-7917.ES.2022.27.46.2200846","article-title":"Increasing number of cases and outbreaks caused by Candida auris in the EU\/EEA, 2020 to 2021","volume":"27","author":"Kohlenberg A","year":"2022","unstructured":"Kohlenberg A, Monnet D, Plachouras D, Candida auris survey collaborative group. Increasing number of cases and outbreaks caused by Candida auris in the EU\/EEA, 2020 to 2021. Euro Surveill. 2022;27(46):2200846\u20132200846.","journal-title":"Euro Surveill"},{"issue":"2","key":"e_1_3_5_7_1","doi-asserted-by":"crossref","first-page":"e143968","DOI":"10.5812\/iji-143968","article-title":"Evaluation of antibiotic susceptibility, carbapenemase and metallobetalactamase-producing strains of Acinetobacter baumannii isolated from hospitalized patients in Zahedan During 2019\u20132022","volume":"10","author":"Jahantigh M","year":"2024","unstructured":"Jahantigh M, Javadi R, Bameri Z, Dehvari A. Evaluation of antibiotic susceptibility, carbapenemase and metallobetalactamase-producing strains of Acinetobacter baumannii isolated from hospitalized patients in Zahedan During 2019\u20132022. Int J Infect. 2024;10(2):e143968.","journal-title":"Int J Infect"},{"issue":"3","key":"e_1_3_5_8_1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10123-024-00563-1","article-title":"Characterization of susceptibility patterns and adaptability of the newly emerged Candida auris","volume":"28","author":"Semenya MD","year":"2025","unstructured":"Semenya MD, Aladejana AE, Ndlovu SI. Characterization of susceptibility patterns and adaptability of the newly emerged Candida auris. Int Microbiol. 2025;28(3):575\u2013587.","journal-title":"Int Microbiol"},{"issue":"4","key":"e_1_3_5_9_1","doi-asserted-by":"crossref","first-page":"ftaa034","DOI":"10.1093\/femspd\/ftaa034","article-title":"Candida auris: a fungus with identity crisis","volume":"78","author":"Vila T","year":"2020","unstructured":"Vila T, Sultan A, Montelongo-Jauregui D, Jabra-Rizk M. Candida auris: a fungus with identity crisis. Pathog Dis. 2020;78(4):ftaa034.","journal-title":"Pathog Dis"},{"key":"e_1_3_5_10_1","first-page":"126621","article-title":"What do we know about the biology of the emerging fungal pathogen of humans Candida auris?","volume":"242","author":"Lorenz A.","year":"2020","unstructured":"Lorenz A. What do we know about the biology of the emerging fungal pathogen of humans Candida auris? Microbiol Res. 2020;242:126621\u2013126621.","journal-title":"Microbiol Res"},{"issue":"9","key":"e_1_3_5_11_1","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3201\/eid2509.190686","article-title":"Potential Fifth Clade of Candida auris, Iran, 2018","volume":"25","author":"Chow N","year":"2019","unstructured":"Chow N, de Groot T, Badali H, Abastabar M, Chiller T, Meis J. Potential Fifth Clade of Candida auris, Iran, 2018. Emerg Infect Dis. 2019;25(9):1780\u20131781.","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"e_1_3_5_12_1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart SR","year":"2017","unstructured":"Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134\u2013140.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"e_1_3_5_13_1","first-page":"e01062\u201301022","article-title":"Clinical performance of the osmotic shock-MALDI MS method to detect Klebsiella pneumoniae carbapenemase in clinical isolates","volume":"60","author":"Lee S","year":"2022","unstructured":"Lee S, Hwang S, Cheon DH, Jang H, Yang WS, Kim MJ, Lee S, Baek J-H. Clinical performance of the osmotic shock-MALDI MS method to detect Klebsiella pneumoniae carbapenemase in clinical isolates. J Clin Microbiol. 2022;60(11):e01062\u201301022.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"e_1_3_5_14_1","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.3390\/jof6010028","article-title":"Aspiring antifungals: review of current antifungal pipeline developments","volume":"6","author":"Gintjee TJ","year":"2020","unstructured":"Gintjee TJ, Donnelley MA, Thompson GR. Aspiring antifungals: review of current antifungal pipeline developments. J Fungi (Basel). 2020;6(1):E28.","journal-title":"J Fungi (Basel)"},{"issue":"2","key":"e_1_3_5_15_1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/biomedicines11020426","article-title":"The urgent threat of Clostridioides difficile infection: a glimpse of the drugs of the future, with related patents and prospects","volume":"11","author":"Alshrari A","year":"2023","unstructured":"Alshrari A, Hudu S, Elmigdadi F, Imran M. The urgent threat of Clostridioides difficile infection: a glimpse of the drugs of the future, with related patents and prospects. Biomedicines. 2023;11(2):426\u2013426.","journal-title":"Biomedicines"},{"issue":"4","key":"e_1_3_5_16_1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3390\/microorganisms9040807","article-title":"Candida auris: epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities","volume":"9","author":"Ahmad S","year":"2021","unstructured":"Ahmad S, Alfouzan W. Candida auris: epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities. Microorganisms. 2021;9(4):807\u2013807.","journal-title":"Microorganisms"},{"issue":"1","key":"e_1_3_5_17_1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3201\/eid2501.181321","article-title":"Candida auris sternal osteomyelitis in a man from Kenya visiting Australia, 2015","volume":"25","author":"Heath C","year":"2019","unstructured":"Heath C, Dyer J, Pang S, Coombs G, Gardam D. Candida auris sternal osteomyelitis in a man from Kenya visiting Australia, 2015. Emerg Infect Dis. 2019;25(1):192\u2013194.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"e_1_3_5_18_1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/myc.12617","article-title":"Otomastoiditis caused by Candida auris: case report and literature review","volume":"60","author":"Choi HI","year":"2017","unstructured":"Choi HI, An J, Hwang JJ, Moon S, Son JS. Otomastoiditis caused by Candida auris: case report and literature review. Mycoses. 2017;60(8):488\u2013492.","journal-title":"Mycoses"},{"issue":"4","key":"e_1_3_5_19_1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3855\/jidc.4582","article-title":"Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis","volume":"9","author":"Kumar D","year":"2015","unstructured":"Kumar D, Banerjee T, Pratap CB, Tilak R. Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis. J Infect Dev Ctries. 2015;9(4):435\u2013437.","journal-title":"J Infect Dev Ctries"},{"issue":"17","key":"e_1_3_5_20_1","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.3390\/jcm14176149","article-title":"A review of current insights in fungal endocarditis","volume":"14","author":"Akritidou O","year":"2025","unstructured":"Akritidou O, Peristeri A-M, Lymperatou D, Prokopidou A, Christaki E, Nikopoulou A. A review of current insights in fungal endocarditis. J Clin Med. 2025;14(17):6149.","journal-title":"J Clin Med"},{"issue":"5","key":"e_1_3_5_21_1","doi-asserted-by":"crossref","first-page":"e1013138","DOI":"10.1371\/journal.ppat.1013138","article-title":"Candida auris is emerging as a prevalent urinary pathogen","volume":"21","author":"La Bella AA","year":"2025","unstructured":"La Bella AA, Santiago-Tirado FH, Flores-Mireles AL. Candida auris is emerging as a prevalent urinary pathogen. PLoS Pathog. 2025;21(5):e1013138.","journal-title":"PLoS Pathog"},{"issue":"9","key":"e_1_3_5_22_1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/pathogens14090903","article-title":"Candidozyma auris spondylodiscitis: a case report from Saudi Arabia and literature review","volume":"14","author":"Sambas R","year":"2025","unstructured":"Sambas R, Aziz KB, Alqahtani FN, Alhathlol H, Alhumaidi M, Alsaedy A, Alhowaish TS. Candidozyma auris spondylodiscitis: a case report from Saudi Arabia and literature review. Pathogens. 2025;14(9):903.","journal-title":"Pathogens"},{"issue":"12","key":"e_1_3_5_23_1","doi-asserted-by":"crossref","first-page":"941","DOI":"10.7326\/L19-0323","article-title":"Panophthalmitis from Candida auris","volume":"171","author":"Shenoy V","year":"2019","unstructured":"Shenoy V, Ballenberger M, Prince A, Maslak S. Panophthalmitis from Candida auris. Ann Intern Med. 2019;171(12):941\u2013943.","journal-title":"Ann Intern Med"},{"issue":"12","key":"e_1_3_5_24_1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3390\/jof10120859","article-title":"Cerebrospinal drain infection by Candida auris: a case report and review of the literature","volume":"10","author":"Halioti A","year":"2024","unstructured":"Halioti A, Vrettou CS, Neromyliotis E, Gavrielatou E, Sarri A, Psaroudaki Z, Magira EE. Cerebrospinal drain infection by Candida auris: a case report and review of the literature. JoF. 2024;10(12):859.","journal-title":"JoF"},{"issue":"5","key":"e_1_3_5_25_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/jof11050362","article-title":"Management of intra-abdominal candidiasis in intensive care setting: a narrative review","volume":"11","author":"Pais MM","year":"2025","unstructured":"Pais MM, Zaragoza R, Mart\u00edn-Loeches I, G\u00f3mez-Bertomeu FF, Rodr\u00edguez A. Management of intra-abdominal candidiasis in intensive care setting: a narrative review. JoF. 2025;11(5):362.","journal-title":"JoF"},{"key":"e_1_3_5_26_1","doi-asserted-by":"crossref","unstructured":"Rhodes J. Current approaches in genome assembly of human fungal pathogens. In: Genome assembly (Methods in molecular biology). New York NY: Springer Nature (Humana Press); 2025. p. 221\u2013246.","DOI":"10.1007\/978-1-0716-4702-8_11"},{"issue":"9","key":"e_1_3_5_27_1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1017\/ice.2017.127","article-title":"Environmental surfaces in healthcare facilities are a potential source for transmission of Candida auris and other Candida species","volume":"38","author":"Piedrahita CT","year":"2017","unstructured":"Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ. Environmental surfaces in healthcare facilities are a potential source for transmission of Candida auris and other Candida species. Infect Control Hosp Epidemiol. 2017;38(9):1107\u20131109.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"e_1_3_5_28_1","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1128\/JCM.00921-17","article-title":"Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface","volume":"55","author":"Welsh RM","year":"2017","unstructured":"Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, Litvintseva AP. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol. 2017;55(10):2996\u20133005.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"e_1_3_5_29_1","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1080\/22221751.2022.2125349","article-title":"Confirmation of fifth Candida auris clade by whole genome sequencing","volume":"11","author":"Spruijtenburg B","year":"2022","unstructured":"Spruijtenburg B, Badali H, Abastabar M, Mirhendi H, Khodavaisy S, Sharifisooraki J, Taghizadeh Armaki M, de Groot T, Meis JF. Confirmation of fifth Candida auris clade by whole genome sequencing. Emerg Microbes Infect. 2022;11(1):2405\u20132411.","journal-title":"Emerg Microbes Infect"},{"issue":"11","key":"e_1_3_5_30_1","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3390\/jof9111101","article-title":"An autochthonous susceptible Candida auris clade I otomycosis case in Iran","volume":"9","author":"Ahmadi B","year":"2023","unstructured":"Ahmadi B, Naeimi B, Ahmadipour MJ, Morovati H, de Groot T, Spruijtenburg B, Badali H, Meis JF. An autochthonous susceptible Candida auris clade I otomycosis case in Iran. JoF. 2023;9(11):1101.","journal-title":"JoF"},{"issue":"4","key":"e_1_3_5_31_1","doi-asserted-by":"crossref","first-page":"e00578","DOI":"10.1002\/mbo3.578","article-title":"Candida auris: a systematic review and meta\u2010analysis of current updates on an emerging multidrug\u2010resistant pathogen","volume":"7","author":"Osei Sekyere J.","year":"2018","unstructured":"Osei Sekyere J. Candida auris: a systematic review and meta\u2010analysis of current updates on an emerging multidrug\u2010resistant pathogen. Microbiologyopen. 2018;7(4):e00578.","journal-title":"Microbiologyopen"},{"issue":"46","key":"e_1_3_5_32_1","doi-asserted-by":"crossref","first-page":"2200846","DOI":"10.2807\/1560-7917.ES.2022.27.46.2200846","article-title":"Increasing number of cases and outbreaks caused by Candida auris in the EU\/EEA, 2020 to 2021","volume":"27","author":"Kohlenberg A","year":"2022","unstructured":"Kohlenberg A, Monnet DL, Plachouras D, Willinger B, Lagrou K, Philipova I, Budimir A, Hadjihannas L, Marcou M, Barekov\u00e1 L, Candida auris survey collaborative group Increasing number of cases and outbreaks caused by Candida auris in the EU\/EEA, 2020 to 2021. Eurosurveillance. 2022;27(46):2200846.","journal-title":"Eurosurveillance"},{"issue":"2","key":"e_1_3_5_33_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.15585\/mmwr.mm7002e3","article-title":"Candida auris outbreak in a COVID-19 specialty care unit\u2014Florida, July\u2013August 2020","volume":"70","author":"Prestel C","year":"2021","unstructured":"Prestel C, Anderson E, Forsberg K, Lyman M, de Perio MA, Kuhar D, Edwards K, Rivera M, Shugart A, Walters M, et al. Candida auris outbreak in a COVID-19 specialty care unit\u2014Florida, July\u2013August 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):56\u201357.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"e_1_3_5_34_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13756-022-01052-8","article-title":"The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature","volume":"11","author":"Thoma R","year":"2022","unstructured":"Thoma R, Seneghini M, Seiffert SN, Vuichard Gysin D, Scanferla G, Haller S, Flury D, Boggian K, Kleger G-R, Filipovic M, et al. The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature. Antimicrob Resist Infect Control. 2022;11(1):12.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"3","key":"e_1_3_5_35_1","first-page":"44","article-title":"Candida auris and COVID-19: a health threatening combination","volume":"8","author":"Khojasteh S","year":"2022","unstructured":"Khojasteh S, Jafarzdeh J, Hosseini SA, Haghani I, Turki H, Gharehbolagh SA, Abastabar M, Mahmoudi S. Candida auris and COVID-19: a health threatening combination. Curr Med Mycol. 2022;8(3):44\u201350.","journal-title":"Curr Med Mycol"},{"issue":"3","key":"e_1_3_5_36_1","doi-asserted-by":"crossref","first-page":"e1011190","DOI":"10.1371\/journal.ppat.1011190","article-title":"Perspective on the origin, resistance, and spread of the emerging human fungal pathogen Candida auris","volume":"19","author":"Sharma C","year":"2023","unstructured":"Sharma C, Kadosh D. Perspective on the origin, resistance, and spread of the emerging human fungal pathogen Candida auris. PLoS Pathog. 2023;19(3):e1011190.","journal-title":"PLoS Pathog"},{"issue":"7","key":"e_1_3_5_37_1","doi-asserted-by":"crossref","first-page":"e00053\u201300022","DOI":"10.1128\/aac.00053-22","article-title":"Candida auris pan-drug-resistant to four classes of antifungal agents","volume":"66","author":"Jacobs SE","year":"2022","unstructured":"Jacobs SE, Jacobs JL, Dennis EK, Taimur S, Rana M, Patel D, Gitman M, Patel G, Schaefer S, Iyer K, et al. Candida auris pan-drug-resistant to four classes of antifungal agents. Antimicrob Agents Chemother. 2022;66(7):e00053\u201300022.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"e_1_3_5_38_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15585\/mmwr.mm6901a2","article-title":"Candida auris isolates resistant to three classes of antifungal medications-New York, 2019","volume":"69","author":"Ostrowsky B","year":"2020","unstructured":"Ostrowsky B, Greenko J, Adams E, Quinn M, O\u2019Brien B, Chaturvedi V, Berkow E, Vallabhaneni S, Forsberg K, Chaturvedi S, C. auris Investigation Work Group, et al. Candida auris isolates resistant to three classes of antifungal medications-New York, 2019. MMWR Morb. Mortal. Wkly. Rep. 2020;69(1):6\u20139.","journal-title":"MMWR Morb. Mortal. Wkly. Rep"},{"issue":"14","key":"e_1_3_5_39_1","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.3390\/jcm12144637","article-title":"Antifungal drug-drug interactions with commonly used pharmaceutics in European pediatric patients with acute lymphoblastic leukemia","volume":"12","author":"Sienkiewicz-Oleszkiewicz B","year":"2023","unstructured":"Sienkiewicz-Oleszkiewicz B, Salamonowicz-Bodzioch M, S\u0142onka J, Ka\u0142wak K. Antifungal drug-drug interactions with commonly used pharmaceutics in European pediatric patients with acute lymphoblastic leukemia. J Clin Med. 2023;12(14):4637.","journal-title":"J Clin Med"},{"issue":"6","key":"e_1_3_5_40_1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jac\/dkae103","article-title":"Triazole antifungal drug interactions\u2014practical considerations for excellent prescribing","volume":"79","author":"Lewis R","year":"2024","unstructured":"Lewis R, Niazi-Ali S, McIvor A, Kanj SS, Maertens J, Bassetti M, Levine D, Groll AH, Denning DW. Triazole antifungal drug interactions\u2014practical considerations for excellent prescribing. J Antimicrob Chemother. 2024;79(6):1203\u20131217.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"e_1_3_5_41_1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/jof7100878","article-title":"International multicentre study of Candida auris infections","volume":"7","author":"Pandya N","year":"2021","unstructured":"Pandya N, Cag Y, Pandak N, Pekok AU, Poojary A, Ayoade F, Fasciana T, Giammanco A, Caskurlu H, Rajani DP, et al. International multicentre study of Candida auris infections. J Fungi (Basel). 2021;7(10):878\u2013878.","journal-title":"J Fungi (Basel)"},{"issue":"7","key":"e_1_3_5_42_1","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/microorganisms13071461","article-title":"Diagnostic approaches for Candida auris: a comprehensive review of screening, identification, and susceptibility testing","volume":"13","author":"Hsu C","year":"2025","unstructured":"Hsu C, Yassin M. Diagnostic approaches for Candida auris: a comprehensive review of screening, identification, and susceptibility testing. Microorganisms. 2025;13(7):1461.","journal-title":"Microorganisms"},{"issue":"2","key":"e_1_3_5_43_1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/microorganisms12020322","article-title":"MALDI-TOF MS: a reliable tool in the real life of the clinical microbiology laboratory","volume":"12","author":"Calderaro A","year":"2024","unstructured":"Calderaro A, Chezzi C. MALDI-TOF MS: a reliable tool in the real life of the clinical microbiology laboratory. Microorganisms. 2024;12(2):322\u2013322.","journal-title":"Microorganisms"},{"issue":"5","key":"e_1_3_5_44_1","doi-asserted-by":"crossref","first-page":"02396","DOI":"10.1128\/AAC.02396-16","article-title":"The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation","volume":"61","author":"Larkin E","year":"2017","unstructured":"Larkin E, Hager C, Chandra J, Mukherjee PK, Retuerto M, Salem I, Long L, Isham N, Kovanda L, Borroto-Esoda K, et al. The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother. 2017;61(5):02396\u201302316.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"e_1_3_5_45_1","doi-asserted-by":"crossref","first-page":"S445","DOI":"10.1093\/infdis\/jix131","article-title":"Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Arendrup MC","year":"2017","unstructured":"Arendrup MC, Patterson TF. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S445\u2013S451.","journal-title":"J Infect Dis"},{"issue":"1","key":"e_1_3_5_46_1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/14756366.2022.2050224","article-title":"Echinocandins-structure, mechanism of action and use in antifungal therapy","volume":"37","author":"Szyma\u0144ski M","year":"2022","unstructured":"Szyma\u0144ski M, Chmielewska S, Czy\u017cewska U, Malinowska M, Tylicki A. Echinocandins-structure, mechanism of action and use in antifungal therapy. J Enzyme Inhib Med Chem. 2022;37(1):876\u2013894.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"5","key":"e_1_3_5_47_1","first-page":"02663","article-title":"Novel ERG11 and TAC1b mutations associated with azole resistance in Candida auris","volume":"65","author":"Li J","year":"2023","unstructured":"Li J, Coste AT, Liechti M, Bachmann D, Sanglard D, Lamoth F. Novel ERG11 and TAC1b mutations associated with azole resistance in Candida auris. Antimicrob Agents Chemother. 2023;65(5):02663\u201302620.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"e_1_3_5_48_1","first-page":"104","article-title":"Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris","volume":"7","author":"Rhodes J","year":"2018","unstructured":"Rhodes J, Abdolrasouli A, Farrer RA, Cuomo CA, Aanensen DM, Armstrong-James D, Fisher MC, Schelenz S. Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris. Emerg Microbes Infect. 2018;7(1):104.","journal-title":"Emerg Microbes Infect"},{"issue":"12","key":"e_1_3_5_49_1","doi-asserted-by":"crossref","first-page":"e01393","DOI":"10.1128\/AAC.01393-19","article-title":"In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism","volume":"63","author":"Bidaud A","year":"2019","unstructured":"Bidaud A, Botterel F, Chowdhary A, Dannaoui E. In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism. Antimicrob Agents Chemother. 2019;63(12):e01393\u201301419. AAC.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"e_1_3_5_50_1","doi-asserted-by":"crossref","first-page":"00684","DOI":"10.1128\/AAC.00684-20","article-title":"Potent synergistic interactions between lopinavir and azole antifungal drugs against emerging multidrug-resistant Candida auris","volume":"65","author":"Eldesouky HE","year":"2020","unstructured":"Eldesouky HE, Salama EA, Lanman NA, Hazbun TR, Seleem MN. Potent synergistic interactions between lopinavir and azole antifungal drugs against emerging multidrug-resistant Candida auris. Antimicrob Agents Chemother. 2020;65(1):00684\u201300620.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_51_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fcimb.2019.00083","article-title":"Identification of off-patent compounds that present antifungal activity against the emerging fungal pathogen Candida auris","volume":"9","author":"De Oliveira HC","year":"2019","unstructured":"De Oliveira HC, Monteiro MC, Rossi SA, Pem\u00e1n J, Ruiz-Gait\u00e1n A, Mendes-Giannini MJS, Mellado E, Zaragoza O. Identification of off-patent compounds that present antifungal activity against the emerging fungal pathogen Candida auris. Front Cell Infect Microbiol. 2019;9:83.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"e_1_3_5_52_1","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1080\/21505594.2020.1838741","article-title":"Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs","volume":"11","author":"Eldesouky H","year":"2020","unstructured":"Eldesouky H, Lanman N, Hazbun T, Seleem M. Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs. Virulence. 2020;11(1):1466\u20131481.","journal-title":"Virulence"},{"issue":"1","key":"e_1_3_5_53_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/pathogens14010040","article-title":"Relationships between Candida auris and the rest of the Candida world\u2014analysis of dual-species biofilms and infections","volume":"14","author":"Janeczko M","year":"2025","unstructured":"Janeczko M, Skrzypek T. Relationships between Candida auris and the rest of the Candida world\u2014analysis of dual-species biofilms and infections. Pathogens. 2025;14(1):40.","journal-title":"Pathogens"},{"issue":"4","key":"e_1_3_5_54_1","first-page":"e59210","article-title":"Fosmanogepix: the novel anti-fungal agent\u2019s comprehensive review of in vitro, in vivo, and current insights from advancing clinical trials","volume":"16","author":"Almajid A","year":"2024","unstructured":"Almajid A, Bazroon A, Al-Awami HM, Albarbari H, Alqahtani I, Almutairi R, Alsuwayj A, Alahmadi F, Aljawad J, Alnimer R, et al. Fosmanogepix: the novel anti-fungal agent\u2019s comprehensive review of in vitro, in vivo, and current insights from advancing clinical trials. Cureus. 2024;16(4):e59210.","journal-title":"Cureus"},{"issue":"3","key":"e_1_3_5_55_1","doi-asserted-by":"crossref","first-page":"02319","DOI":"10.1128\/AAC.02319-17","article-title":"In vitro and in vivo evaluation of the antifungal activity of APX001A\/APX001 against Candida auris","volume":"62","author":"Hager CL","year":"2018","unstructured":"Hager CL, Larkin EL, Long L, Zohra Abidi F, Shaw KJ, Ghannoum MA. In vitro and in vivo evaluation of the antifungal activity of APX001A\/APX001 against Candida auris. Antimicrob Agents Chemother. 2018;62(3):02319\u201302317.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"e_1_3_5_56_1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-023-01891-8","article-title":"Rezafungin: first approval","volume":"83","author":"Syed YY.","year":"2023","unstructured":"Syed YY. Rezafungin: first approval. Drugs. 2023;83(9):833\u2013840.","journal-title":"Drugs"},{"issue":"3","key":"e_1_3_5_57_1","doi-asserted-by":"crossref","first-page":"02136","DOI":"10.1128\/AAC.02136-19","article-title":"In vitro activity of ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with the activities of six comparator agents","volume":"64","author":"Arendrup MC","year":"2020","unstructured":"Arendrup MC, J\u00f8rgensen KM, Hare RK, Chowdhary A. In vitro activity of ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with the activities of six comparator agents. Antimicrob Agents Chemother. 2020;64(3):02136\u201302119.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"e_1_3_5_58_1","doi-asserted-by":"crossref","first-page":"02611","DOI":"10.1128\/AAC.02611-18","article-title":"A novel 1, 3-beta-d-glucan inhibitor, ibrexafungerp (formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis","volume":"63","author":"Larkin E","year":"2019","unstructured":"Larkin E, Long L, Isham N, Borroto-Esoda K, Barat S, Angulo D, Wring S, Ghannoum M. A novel 1, 3-beta-d-glucan inhibitor, ibrexafungerp (formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis. Antimicrob Agents Chemother. 2019;63(5):02611\u201302618.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"e_1_3_5_59_1","doi-asserted-by":"crossref","first-page":"00570","DOI":"10.1128\/AAC.00570-17","article-title":"Crystal structure of the new investigational drug candidate VT-1598 in complex with Aspergillus fumigatus sterol 14\u03b1-demethylase provides insights into its broad-spectrum antifungal activity","volume":"61","author":"Hargrove TY","year":"2017","unstructured":"Hargrove TY, Garvey EP, Hoekstra WJ, Yates CM, Wawrzak Z, Rachakonda G, Villalta F, Lepesheva GI. Crystal structure of the new investigational drug candidate VT-1598 in complex with Aspergillus fumigatus sterol 14\u03b1-demethylase provides insights into its broad-spectrum antifungal activity. Antimicrob Agents Chemother. 2017;61(7):00570\u201300517.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"e_1_3_5_60_1","doi-asserted-by":"crossref","first-page":"02233","DOI":"10.1128\/AAC.02233-18","article-title":"The fungal Cyp51-specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris","volume":"63","author":"Wiederhold NP","year":"2019","unstructured":"Wiederhold NP, Lockhart SR, Najvar LK, Berkow EL, Jaramillo R, Olivo M, Garvey EP, Yates CM, Schotzinger RJ, Catano G, et al. The fungal Cyp51-specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris. Antimicrob Agents Chemother. 2019;63(3):02233\u201302218.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"e_1_3_5_61_1","doi-asserted-by":"crossref","first-page":"e00690","DOI":"10.1002\/prp2.690","article-title":"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent","volume":"9","author":"Cass L","year":"2021","unstructured":"Cass L, Murray A, Davis A, Woodward K, Albayaty M, Ito K, Strong P, Ayrton J, Brindley C, Prosser J, et al. Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. Pharmacol Res Perspect. 2021;9(1):e00690.","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"e_1_3_5_62_1","doi-asserted-by":"crossref","first-page":"02280","DOI":"10.1128\/AAC.02280-16","article-title":"In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on Aspergillus fumigatus infection","volume":"61","author":"Colley T","year":"2017","unstructured":"Colley T, Alanio A, Kelly SL, Sehra G, Kizawa Y, Warrilow AGS, Parker JE, Kelly DE, Kimura G, Anderson-Dring L, et al. In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on Aspergillus fumigatus infection. Antimicrob Agents Chemother. 2017;61(5):02280\u201302216.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_63_1","doi-asserted-by":"crossref","unstructured":"Vicente F Reyes F Genilloud O. New antifungal drugs: discovery and therapeutic potential. In: Fungi bioactive metabolites: Integration of pharmaceutical applications. Singapore: Springer Nature; 2024. p. 371\u2013400.","DOI":"10.1007\/978-981-99-5696-8_12"},{"issue":"11","key":"e_1_3_5_64_1","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/jac\/dky255","article-title":"Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline","volume":"73","author":"Wijma RA","year":"2018","unstructured":"Wijma RA, Huttner A, Koch BC, Mouton JW, Muller AE. Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline. J Antimicrob Chemother. 2018;73(11):2916\u20132926.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"e_1_3_5_65_1","doi-asserted-by":"crossref","first-page":"1697. e1697","DOI":"10.1016\/j.cmi.2021.06.035","article-title":"Antifungal activity of nitroxoline against Candida auris isolates","volume":"27","author":"Fuchs F","year":"2021","unstructured":"Fuchs F, Hof H, Hofmann S, Kurzai O, Meis JF, Hamprecht A. Antifungal activity of nitroxoline against Candida auris isolates. Clinical Microbiology and Infection. 2021;27(11):1697. e1697\u20131697. e1610.","journal-title":"Clinical Microbiology and Infection"},{"issue":"6","key":"e_1_3_5_66_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/biom9060205","article-title":"Effects of the natural peptide crotamine from a South American Rattlesnake on Candida auris, an emergent multidrug antifungal resistant human pathogen","volume":"9","author":"Dal Mas C","year":"2019","unstructured":"Dal Mas C, Rossato L, Shimizu T, Oliveira EB, da Silva Junior PI, Meis JF, Colombo AL, Hayashi MA. Effects of the natural peptide crotamine from a South American Rattlesnake on Candida auris, an emergent multidrug antifungal resistant human pathogen. Biomolecules. 2019;9(6):205.","journal-title":"Biomolecules"},{"issue":"38","key":"e_1_3_5_67_1","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.2174\/138161211798999429","article-title":"Crotamine, a small basic polypeptide myotoxin from rattlesnake venom with cell-penetrating properties","volume":"17","author":"R\u00e1dis-Baptista G","year":"2011","unstructured":"R\u00e1dis-Baptista G, Kerkis I. Crotamine, a small basic polypeptide myotoxin from rattlesnake venom with cell-penetrating properties. Curr Pharm Des. 2011;17(38):4351\u20134361.","journal-title":"Curr Pharm Des"},{"issue":"10","key":"e_1_3_5_68_1","doi-asserted-by":"crossref","first-page":"01084","DOI":"10.1128\/AAC.01084-18","article-title":"Screening a repurposing library for inhibitors of multidrug-resistant Candida auris identifies ebselen as a repositionable candidate for antifungal drug development","volume":"62","author":"Wall G","year":"2018","unstructured":"Wall G, Chaturvedi AK, Wormley FL, JrWiederhold NP, Patterson HP, Patterson TF, Lopez-Ribot JL. Screening a repurposing library for inhibitors of multidrug-resistant Candida auris identifies ebselen as a repositionable candidate for antifungal drug development. Antimicrob Agents Chemother. 2018;62(10):01084\u201301018.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"e_1_3_5_69_1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1128\/AEM.67.7.2982-2992.2001","article-title":"Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol","volume":"67","author":"Hornby JM","year":"2001","unstructured":"Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, Shoemaker R, Dussault P, Nickerson KW. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol. 2001;67(7):2982\u20132992.","journal-title":"Appl Environ Microbiol"},{"issue":"5","key":"e_1_3_5_70_1","doi-asserted-by":"crossref","first-page":"e0233102","DOI":"10.1371\/journal.pone.0233102","article-title":"Abrogation of pathogenic attributes in drug resistant Candida auris strains by farnesol","volume":"15","author":"Srivastava V","year":"2020","unstructured":"Srivastava V, Ahmad A. Abrogation of pathogenic attributes in drug resistant Candida auris strains by farnesol. PLoS One. 2020;15(5):e0233102\u2013e0233102.","journal-title":"PLoS One"},{"issue":"16","key":"e_1_3_5_71_1","doi-asserted-by":"crossref","first-page":"9264","DOI":"10.3390\/ijms23169264","article-title":"Antimicrobial peptides with anti-Candida activity","volume":"23","author":"Perez-Rodriguez A","year":"2022","unstructured":"Perez-Rodriguez A, Eraso E, Quind\u00f3s G, Mateo E. Antimicrobial peptides with anti-Candida activity. Int J Mol Sci. 2022;23(16):9264.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"e_1_3_5_72_1","doi-asserted-by":"crossref","first-page":"00374","DOI":"10.1128\/AAC.00374-19","article-title":"The novel arylamidine T-2307 selectively disrupts yeast mitochondrial function by inhibiting respiratory chain complexes","volume":"63","author":"Yamashita K","year":"2019","unstructured":"Yamashita K, Miyazaki T, Fukuda Y, Mitsuyama J, Saijo T, Shimamura S, Yamamoto K, Imamura Y, Izumikawa K, Yanagihara K, et al. The novel arylamidine T-2307 selectively disrupts yeast mitochondrial function by inhibiting respiratory chain complexes. Antimicrob Agents Chemother. 2019;63(8):00374\u201300319.","journal-title":"Antimicrob Agents Chemother"},{"issue":"24","key":"e_1_3_5_73_1","doi-asserted-by":"crossref","first-page":"16042","DOI":"10.3390\/ijms232416042","article-title":"The arylamidine T-2307 as a Novel treatment for the prevention and eradication of Candida tropicalis biofilms","volume":"23","author":"Maione A","year":"2022","unstructured":"Maione A, La Pietra A, Siciliano A, Mileo A, De Falco M, de Alteriis E, Guida M, Galdiero E. The arylamidine T-2307 as a Novel treatment for the prevention and eradication of Candida tropicalis biofilms. Int J Mol Sci. 2022;23(24):16042.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_5_74_1","doi-asserted-by":"crossref","first-page":"1610743","DOI":"10.3389\/fcimb.2025.1610743","article-title":"AI in fungal drug development: opportunities, challenges, and future outlook","volume":"15","author":"Li Y","year":"2025","unstructured":"Li Y, Qiao Y, Ma Y, Xue P, Ding C. AI in fungal drug development: opportunities, challenges, and future outlook. Front Cell Infect Microbiol. 2025;15:1610743.","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"e_1_3_5_75_1","doi-asserted-by":"crossref","first-page":"2400280","DOI":"10.1002\/smsc.202400280","article-title":"Transformative impact of nanocarrier-mediated drug delivery: overcoming biological barriers and expanding therapeutic horizons","volume":"4","author":"Kim M","year":"2024","unstructured":"Kim M, Shin M, Zhao Y, Ghosh M, Son Y-O. Transformative impact of nanocarrier-mediated drug delivery: overcoming biological barriers and expanding therapeutic horizons. Small Sci. 2024;4(11):2400280.","journal-title":"Small Sci"},{"key":"e_1_3_5_76_1","doi-asserted-by":"crossref","first-page":"1641373","DOI":"10.3389\/fcimb.2025.1641373","article-title":"Innovative antifungal strategies to combat drug-resistant Candida auris: recent advances and clinical implications","volume":"15","author":"Du W","year":"2025","unstructured":"Du W, Wang Q, Zhao M. Innovative antifungal strategies to combat drug-resistant Candida auris: recent advances and clinical implications. Front Cell Infect Microbiol. 2025;15:1641373.","journal-title":"Front Cell Infect Microbiol"},{"key":"e_1_3_5_77_1","doi-asserted-by":"crossref","first-page":"1662442","DOI":"10.3389\/fcimb.2025.1662442","article-title":"New antifungal strategies and drug development against WHO critical priority fungal pathogens","volume":"15","author":"Li Y","year":"2025","unstructured":"Li Y, Liu Y, Jiang Y, Yang Y, Ni W, Zhang W, Tan L. New antifungal strategies and drug development against WHO critical priority fungal pathogens. Front Cell Infect Microbiol. 2025;15:1662442\u20131662442.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"e_1_3_5_78_1","doi-asserted-by":"crossref","first-page":"6816002","DOI":"10.1155\/ipid\/6816002","article-title":"A critical review of the prospect of integrating artificial intelligence in infectious disease diagnosis and prognosis","volume":"2025","author":"Hudu SA","year":"2025","unstructured":"Hudu SA, Alshrari AS, Abu-Shoura E, Osman A, Jimoh AO. A critical review of the prospect of integrating artificial intelligence in infectious disease diagnosis and prognosis. Interdiscip Perspect Infect Dis. 2025;2025(1):6816002.","journal-title":"Interdiscip Perspect Infect Dis"},{"issue":"2","key":"e_1_3_5_79_1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/ph19020286","article-title":"Phage display-derived peptides have neutralizing activities against biofilm formation by Candida albicans, Candidozyma auris and Candida parapsilosis","volume":"19","author":"Bolotnikov G","year":"2026","unstructured":"Bolotnikov G, Gruber D, Walter J-C, K\u00fchnel K, Kemal T, Rodriguez A, Preising N, St\u00e4ndker L, Firacative C, Spellerberg B, et al. Phage display-derived peptides have neutralizing activities against biofilm formation by Candida albicans, Candidozyma auris and Candida parapsilosis. Pharmaceuticals. 2026;19(2):286.","journal-title":"Pharmaceuticals"},{"issue":"5","key":"e_1_3_5_80_1","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1007\/s13346-024-01749-w","article-title":"Nanoparticles in the battle against Candida auris biofilms: current advances and future prospects","volume":"15","author":"Fayed B.","year":"2025","unstructured":"Fayed B. Nanoparticles in the battle against Candida auris biofilms: current advances and future prospects. Drug Deliv Transl Res. 2025;15(5):1496\u20131512.","journal-title":"Drug Deliv Transl Res"},{"key":"e_1_3_5_81_1","doi-asserted-by":"crossref","first-page":"1701446","DOI":"10.3389\/fphar.2025.1701446","article-title":"An overview of the mechanistic approaches of antifungal nanomaterials","volume":"16","author":"Saha S","year":"2025","unstructured":"Saha S, Sachivkina N, Gurina R, Neborak E, Zhabo N, Avdonina M, Molchanova M. An overview of the mechanistic approaches of antifungal nanomaterials. Front Pharmacol. 2025;16:1701446.","journal-title":"Front Pharmacol"},{"issue":"3","key":"e_1_3_5_82_1","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1007\/s12668-024-01478-x","article-title":"Development of alginate and chitosan nanoparticles as carriers of Zingiber officinale essential oil for enhancement of its anticancer, antibacterial, and antifungal activities","volume":"14","author":"Zarenezhad E","year":"2024","unstructured":"Zarenezhad E, Afsarian MH, Alipanah H, Yarian F, Moradi H, Khalaf H-E, Osanloo M. Development of alginate and chitosan nanoparticles as carriers of Zingiber officinale essential oil for enhancement of its anticancer, antibacterial, and antifungal activities. BioNanoSci. 2024;14(3):3301\u20133312.","journal-title":"BioNanoSci"},{"key":"e_1_3_5_83_1","doi-asserted-by":"crossref","unstructured":"Eedara BB Encinas-Basurto D Manivannan B Hayes D Jr Mansour HM. Inhalable nanomedicines for the treatment of pulmonary aspergillosis. In: Nanomedicines for the prevention and treatment of infectious diseases. Cham Switzerland: Springer International Publishing; 2023. p. 77\u201394.","DOI":"10.1007\/978-3-031-39020-3_3"},{"issue":"2","key":"e_1_3_5_84_1","doi-asserted-by":"crossref","first-page":"03333","DOI":"10.1128\/mBio.03333-20","article-title":"Genome-wide analysis of experimentally evolved Candida auris reveals multiple novel mechanisms of multidrug resistance","volume":"12","author":"Carolus H","year":"2021","unstructured":"Carolus H, Pierson S, Mu\u00f1oz JF, Suboti\u0107 A, Cruz RB, Cuomo CA, Van Dijck P. Genome-wide analysis of experimentally evolved Candida auris reveals multiple novel mechanisms of multidrug resistance. mBio. 2021;12(2):03333\u201303320.","journal-title":"mBio"},{"issue":"3","key":"e_1_3_5_85_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1039\/D4MO00222A","article-title":"Revealing the dynamics of fungal disease with proteomics","volume":"21","author":"Sa M","year":"2025","unstructured":"Sa M, da Silva M, Ball B, Geddes-McAlister J. Revealing the dynamics of fungal disease with proteomics. Mol Omics. 2025;21(3):173\u2013184.","journal-title":"Mol Omics"},{"issue":"2","key":"e_1_3_5_86_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/jof11020093","article-title":"Fungal metabolomics: a comprehensive approach to understanding pathogenesis in humans and identifying potential therapeutics","volume":"11","author":"Alves V","year":"2025","unstructured":"Alves V, Zamith-Miranda D, Frases S, Nosanchuk JD. Fungal metabolomics: a comprehensive approach to understanding pathogenesis in humans and identifying potential therapeutics. JoF. 2025;11(2):93.","journal-title":"JoF"}],"container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2660982","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14756366.2026.2660982","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2660982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:47:56Z","timestamp":1784551676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14756366.2026.2660982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14756366.2026.2660982"],"URL":"https:\/\/doi.org\/10.1080\/14756366.2026.2660982","relation":{},"ISSN":["1475-6366","1475-6374"],"issn-type":[{"value":"1475-6366","type":"print"},{"value":"1475-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2660982"}}